Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELCHRONO: Chrono-immunotherapy for Advanced Melanoma
NCT07574047Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, pembrolizumab, ipilimumab, relatlimab in melanoma, sponsored by Swiss Group for Clinical Cancer Research. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07574047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574047.